Condition: Covid19 · Sponsor: Suzhou Kintor Pharmaceutical Inc,
This study is an adaptive Phase III randomized double-blind placebo-controlled trial to evaluate the efficacy and safety of Proxalutamide (GT0918) in hospitalized adults diagnosed with COVID-19. The study is a multicenter trial that will be conducted globally. The study will compare GT0918 plus standard of care (SOC) with the placebo plus SOC. Approximately 762 subjects will be randomized in a 1:1 ratio to either GT0918 plus SOC or placebo plus SOC group.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Alternative Research Associates LLC. | Hialeah, Florida, United States | — |
| Sparrow Hospital | Lansing, Michigan, United States | — |
| Hannibal Clinic (HC) | Hannibal, Missouri, United States | — |
| Raymond G. Murphy VA Medical Center | Albuquerque, New Mexico, United States | — |
| Saint Lawrence Health System | New York, New York, United States | — |
| Ascension St. John Medical Center | Tulsa, Oklahoma, United States | — |
| Medical City Fort Worth | Fort Worth, Texas, United States | — |
| PRX Research | Mesquite, Texas, United States | — |
| Shanghai Public Health Clinical Center | Jinshan, Shanghai Municipality, China | — |
| The Third People's Hospital of Shenzhen | Longgang District, Shenzhen, China | — |
| Beijing Ditan Hospital Capital Medical University | Beijing, China | — |
| Davao Doctors Hospital | Davao City, Davao Region, Philippines | — |
+ 18 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05009732